Screening Tools for Cognitive Impairment in Adults with Substance Use Disorders: A Systematic Review

• Published in: Journal of the International Neuropsychological Society Vol. 28; no. 7; pp. 756 - 779
• Main Authors: Ko, Katherine Y., Ridley, Nicole, Bryce, Shayden D., Allott, Kelly, Smith, Angela, Kamminga, Jody
• Format: Journal Article
• Language: English
• Published: New York, USA Cambridge University Press 01.08.2022
• Subjects: Adult; Adults; Classification; Cognition & reasoning; Cognitive ability; Cognitive Dysfunction - diagnosis; Cognitive Dysfunction - etiology; Critical Review; Decision making; Dementia; Dementia - diagnosis; Drug use; Executive function; Humans; Illnesses; Mental Status and Dementia Tests; Neuropsychology; Population studies; Quality control; Reviews; Sensitivity and Specificity; Subject heading schemes; Substance abuse treatment; Substance use; Substance use disorder; Substance-Related Disorders - complications; Substance-Related Disorders - diagnosis; Systematic review; Screening; Cognition; Adults; Neuropsychology; Substance-related disorders
• ISSN: 1355-6177; 1469-7661; 1469-7661
• DOI: 10.1017/S135561772100103X

Cognitive impairment is common in individuals with substance use disorders (SUDs), yet no evidence-based guidelines exist regarding the most appropriate screening measure for use in this population. This systematic review aimed to (1) describe different cognitive screening measures used in adults with SUDs, (2) identify substance use populations and contexts these tools are utilised in, (3) review diagnostic accuracy of these screening measures versus an accepted objective reference standard, and (4) evaluate methodology of included studies for risk of bias. Online databases (PsycINFO, MEDLINE, Embase, and CINAHL) were searched for relevant studies according to pre-determined criteria, and risk of bias and applicability was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). At each review phase, dual screening, extraction, and quality ratings were performed. Fourteen studies met inclusion, identifying 10 unique cognitive screening tools. The Montreal Cognitive Assessment (MoCA) was the most common, and two novel screening tools (Brief Evaluation of Alcohol-Related Neuropsychological Impairments [BEARNI] and Brief Executive Function Assessment Tool [BEAT]) were specifically developed for use within SUD populations. Twelve studies reported on classification accuracy and relevant psychometric parameters (e.g., sensitivity and specificity). While several tools yielded to classification accuracy, there was poor adherence to the Standards for Reporting Diagnostic Accuracy Studies (STARD) across all studies, with high or unclear risk of methodological bias. While some screening tools exhibit promise for use within SUD populations, further evaluation with stronger methodological design and reporting is required. Clinical recommendations and future directions for research are discussed.